A brand new editorial paper was printed in Oncotarget titled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”
On this new editorial, researchers Alessia Roma, Lawrence D. Goodridge, and Paul A. Spagnuolo from the College of Guelph focus on acute myeloid leukemia (AML)—an aggressive most cancers of the blood and bone marrow outlined by poor affected person outcomes and sub-optimal therapeutics.
Current developments in our understanding of AML biology convey optimism to bettering affected person outcomes for this devastating illness. For instance, discovering and validating metabolic vulnerabilities distinct to AML opens new methods for novel drug growth.
In reality, since 2017, a 3rd of newly authorized AML therapeutics have focused metabolic abnormalities. Thus, additional identification and elucidation of metabolic vulnerabilities in AML might result in novel therapies to enhance affected person outcomes.
“One strategy is to weaken tumor cell survival mechanisms. On this regard, exploring reductive carboxylation as a attainable drug goal might present new avenues for optimizing current therapies aimed toward bettering AML affected person outcomes,” the researchers conclude.
Alessia Roma et al, Reductive carboxylation of glutamine as a possible goal in acute myeloid leukemia, Oncotarget (2023). DOI: 10.18632/oncotarget.28474
Impression Journals LLC
Reductive carboxylation of glutamine as a possible goal in acute myeloid leukemia (2024, January 16)
retrieved 16 January 2024
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.